title: Angiotensin II receptor blockade and insulin sensitivity in overweight and obese adults with elevated blood pressure.
abstract: We tested the hypothesis that olmesartan, an angiotensin II receptor blocker (ARB) devoid of peroxisome proliferator-activated receptor γ agonist activity, would improve whole-body insulin sensitivity in overweight and obese individuals with elevated blood pressure (BP). Sixteen individuals (8 women, 8 men; age=49.5 ± 2.9 years; body mass index=33.0 ± 1.7 kg/m2) were randomly assigned in a crossover manner to control and ARB interventions. Insulin sensitivity was determined from intravenous glucose tolerances tests before and after each 8-week intervention. BP, body weight, body fat, lipid and lipoprotein concentrations, and insulin sensitivity were similar at baseline for both treatments (all p > 0.05). Diastolic BP and triglyceride concentrations were higher (p = 0.007 and 0.042 respectively) at baseline for the ARB compared with the control intervention. Systolic (-11.7 mmHg; p = 0.008) and diastolic (-12.1 mmHg; p = 0.0001) BP decreased, however insulin sensitivity did not change (p > 0.05) following ARB treatment. Furthermore, there were no significant correlates of changes in insulin sensitivity following the ARB intervention. In summary, our findings indicate that short-term ARB treatment did not affect whole-body insulin sensitivity in overweight or obese individuals with elevated BP. Future studies are needed to clarify the effect of individual ARBs on insulin sensitivity in obesity.
authors: Human Integrative Physiology Laboratory, Department of Human Nutrition, Foods and Exercise, Virginia Polytechnic Institute and State University, Blacksburg, VA, USA.
authors: Elaina L
authors: EL
authors: Marinik
authors: Madlyn I
authors: MI
authors: Frisard
authors: Matthew W
authors: MW
authors: Hulver
authors: Brenda M
authors: BM
authors: Davy
authors: Jose M
authors: JM
authors: Rivero
authors: Jyoti S
authors: JS
authors: Savla
authors: Kevin P
authors: KP
authors: Davy
mesh_terms: D057911:Angiotensin Receptor Antagonists / Q000627:therapeutic use*; D001706:Biopsy; D018592:Cross-Over Studies; D005260:Female; D005951:Glucose Tolerance Test; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D007093:Imidazoles / Q000627:therapeutic use*; D007333:Insulin Resistance / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D018482:Muscle, Skeletal / Q000378:metabolism; D009765:Obesity / Q000150:complications / Q000378:metabolism*; D050177:Overweight / Q000150:complications / Q000378:metabolism*; D012084:Renin-Angiotensin System / Q000187:drug effects / Q000502:physiology; D013777:Tetrazoles / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D057911:Angiotensin Receptor Antagonists; D007093:Imidazoles; D013777:Tetrazoles; C437965:olmesartan